Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lazertinib in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Metastatic Non-Small Cell Lung Cancer With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR Tyrosine Kinase Inhibitor

NCT05326425 is registered in ClinicalTrials.gov with Jin Hyoung Kang as lead sponsor.

NCT NCT05326425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05326425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lazertinib in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Metastatic Non-Small Cell Lung Cancer With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR Tyrosine Kinase Inhibitor
Lead sponsor
Jin Hyoung Kang
Phase
Phase 2
Overall status
Unknown status
Start date
June 23, 2021
Completion date
June 30, 2024
Enrollment
40 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lung neoplasms